POINT Biopharma Investor Presentation September 2023

POINT Biopharma Global Inc. presents its next-generation radioligands platform for cancer treatment, including clinical-stage programs PNT2002 (prostate cancer) and PNT2003 (neuroendocrine tumors) with partnerships generating up to $1.8B in milestone and royalty payments. The company operates a state-of-the-art GMP manufacturing facility and maintains a cash runway into 2026 with $435M in liquidity.